Skip to main content
    • Aa
    • Aa

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

  • Sagar Agarwal (a1) (a2), Ramola Sane (a1) (a2), Rajneet Oberoi (a1) (a2), John R. Ohlfest (a1) (a2) (a3) (a4) and William F. Elmquist (a1) (a2)...

Glioblastoma multiforme, because of its invasive nature, can be considered a disease of the entire brain. Despite recent advances in surgery, radiotherapy and chemotherapy, current treatment regimens have only a marginal impact on patient survival. A crucial challenge is to deliver drugs effectively to invasive glioma cells residing in a sanctuary within the central nervous system. The blood–brain barrier (BBB) restricts the delivery of many small and large molecules into the brain. Drug delivery to the brain is further restricted by active efflux transporters present at the BBB. Current clinical assessment of drug delivery and hence efficacy is based on the measured drug levels in the bulk tumour mass that is usually removed by surgery. Mounting evidence suggests that the inevitable relapse and lethality of glioblastoma multiforme is due to a failure to effectively treat invasive glioma cells. These invasive cells hide in areas of the brain that are shielded by an intact BBB, where they continue to grow and give rise to the recurrent tumour. Effective delivery of chemotherapeutics to the invasive glioma cells is therefore critical, and long-term efficacy will depend on the ability of a molecularly targeted agent to penetrate an intact and functional BBB throughout the entire brain. This review highlights the various aspects of the BBB, and also the brain–tumour-cell barrier (a barrier due to expression of efflux transporters in tumour cells), that together can significantly influence drug response. It then discusses the challenge of glioma as a disease of the whole brain, which lends emphasis to the need to deliver drugs effectively across the BBB to reach both the central tumour and the invasive glioma cells.

Corresponding author
*Corresponding author: William F. Elmquist, Department of Pharmaceutics, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA. E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

4R. Stupp (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 352, 987-996

5P.Y. Wen and A.A. Brandes (2009) Treatment of recurrent high-grade gliomas. Current Opinion in Neurology 22, 657-664

6W.M. Pardridge (2005) The blood–brain barrier: bottleneck in brain drug development. NeuroRx 2, 3-14

() . , -8D.N. Louis 2007 The 2007 WHO classification of tumours of the central nervous system Acta Neuropathologica 114 97109

9H. Ohgaki and P. Kleihues (2007) Genetic pathways to primary and secondary glioblastoma. American Journal of Pathology 170, 1445-1453

10E.A. Maher (2006) Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Research 66, 11502-11513

11Y. Liang (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America 102, 5814-5819

12Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068

13P.Y. Wen and S. Kesari (2008) Malignant gliomas in adults. New England Journal of Medicine 359, 492-507

14T.N. Kreisl (2009) Chemotherapy for malignant gliomas. Seminars in Radiation Oncology 19, 150-154

15M.J. McGirt (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. Journal of Neurosurgery 110, 156-162

16M. Lacroix (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Journal of Neurosurgery 95, 190-198

19T.A. Libermann (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144-147

20J.N. Rich and D.D. Bigner (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nature Reviews. Drug Discovery 3, 430-446

23A. Guha (1995) Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. International Journal of Cancer 60, 168-173

24E.A. Maher (2001) Malignant glioma: genetics and biology of a grave matter. Genes and Development 15, 1311-1333

25N.O. Schmidt (1999) Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. International Journal of Cancer 84, 10-18

26K.H. Plate (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848

27A. Mukasa (2010) Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proceedings of the National Academy of Sciences of the United States of America 107, 2616-2621

30F. Griffero (2009) Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. Journal of Biological Chemistry 284, 7138-7148

31M.E. Halatsch (2004) Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. Journal of Neurosurgery 100, 523-533

32M. Preusser (2008) Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. Journal of Neurooncology 89, 211-218

33E. Franceschi (2007) Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). British Journal of Cancer 96, 1047-1051

34J.N. Rich (2004) Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology 22, 133-142

35D.A. Reardon (2009) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neurooncology 96, 219-230

36M.D. Prados (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Journal of Clinical Oncology 27, 579-584

37J.J. Raizer (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-oncology 12, 95-103

38D.M. Peereboom (2009) Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. Journal of Neurooncology 98, 93-99

40R. Capdeville (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews. Drug Discovery 1, 493-502

41E. Ranza (2009) In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. Journal of Neurooncology 96, 349-357

42L. Geng (2006) STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. International Journal of Radiation Oncology, Biology, Physics 64, 263-271

44P.Y. Wen (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clinical Cancer Research 12, 4899-4907

45E. Raymond (2008) Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. Journal of Clinical Oncology 26, 4659-4665

47T.T. Batchelor (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95

48T.T. Batchelor (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Journal of Clinical Oncology 28, 2817-2823

49T.N. Kreisl (2009) A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). Journal of Neurooncology 92, 99-105

50D.A. Reardon (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Journal of Clinical Oncology 23, 9359-9368

51A. Desjardins (2007) Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. Journal of Neurooncology 83, 53-60

54E. Galanis (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology 23, 5294-5304

56W.S. Kamoun (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. Journal of Clinical Oncology 27, 2542-2552

57S.M. Wilhelm (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics 7, 3129-3140

58A.M. O'Farrell (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101, 3597-3605

59S. de Bouard (2007) Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro-oncology 9, 412-423

60M.D. Siegelin (2010) Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett 478, 165-170

61J.N. Rich (2005) ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clinical Cancer Research 11, 8145-8157

62J.J. Yiin (2010) ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Molecular Cancer Therapeutics 9, 929-941

63X. Hu (2005) mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7, 356-368

64J. Lee (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403

65B.T. Hawkins and T.P. Davis (2005) The blood–brain barrier/neurovascular unit in health and disease. Pharmacological Reviews 57, 173-185

66W.M. Pardridge (1999) Blood–brain barrier biology and methodology. Journal of Neurovirology 5, 556-569

67W.M. Pardridge (1998) CNS drug design based on principles of blood–brain barrier transport. Journal of Neurochemistry 70, 1781-1792

68Ajay, G.W. Bemis and M.A. Murcko (1999) Designing libraries with CNS activity. Journal of Medicinal Chemistry 42, 4942-4951

69S. Vilar , M. Chakrabarti and S. Costanzi (2010) Prediction of passive blood–brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors. Journal of Molecular Graphics and Modelling 28, 899-903

70K.M. Mahar Doan (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. Journal of Pharmacology and Experimental Therapeutics 303, 1029-1037

71P.L. Golden and G.M. Pollack (2003) Blood–brain barrier efflux transport. Journal of Pharmaceutical Sciences 92, 1739-1753

72H. Kusuhara and Y. Sugiyama (2005) Active efflux across the blood–brain barrier: role of the solute carrier family. NeuroRx 2, 73-85

73H. Sun (2003) Drug efflux transporters in the CNS. Advanced Drug Delivery Reviews 55, 83-105

74J.A. Nicolazzo and K. Katneni (2009) Drug transport across the blood–brain barrier and the impact of breast cancer resistance protein (ABCG2). Current Topics in Medicinal Chemistry 9, 130-147

75P. Borst (2000) A family of drug transporters: the multidrug resistance-associated proteins. Journal of the National Cancer Institute 92, 1295-1302

76A.H. Schinkel and J.W. Jonker (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advanced Drug Delivery Reviews 55, 3-29

77A.H. Schinkel (1999) P-glycoprotein, a gatekeeper in the blood–brain barrier. Advanced Drug Delivery Reviews 36, 179-194

78W. Loscher and H. Potschka (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Progress in Neurobiology 76, 22-76

79R.L. Juliano and V. Ling (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta 455, 152-162

80K. Ueda (1986) The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochemical and Biophysical Research Communications 141, 956-962

81C. Cordon-Cardo (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proceedings of the National Academy of Sciences of the United States of America 86, 695-698

82F. Thiebaut (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. Journal of Histochemistry and Cytochemistry 37, 159-164

83M.A. Barrand , K.J. Robertson and S.F. von Weikersthal (1995) Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Letters 374, 179-183

85A. Tsuji (1992) P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sciences 51, 1427-1437

86E. Beaulieu (1997) P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochemical Journal 326 (Pt 2), 539-544

87A.H. Schinkel (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77, 491-502

88A.H. Schinkel (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proceedings of the National Academy of Sciences of the United States of America 94, 4028-4033

89J.W. Jonker (2005) Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 23, 1059-1065

90R.L. Fine (2006) Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clinical Cancer Research 12, 5770-5776

91M.W. Pitz (2011) Tissue concentration of systemically administered antineoplastic agents in human brain tumors. Journal of Neurooncology Mar 12; [Epub ahead of print]

92S. Fattori (2007) Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Virchows Archiv 451, 81-87

94S.M. Ashmore , D.G. Thomas and J.L. Darling (1999) Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma? Anticancer Drugs 10, 861-872

95L.A. Doyle and D.D. Ross (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340-7358

96S. Zhou (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine 7, 1028-1034

97A. Haimeur (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Current Drug Metabolism 5, 21-53

98H. Huai-Yun (1998) Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochemical and Biophysical Research Communications 243, 816-820

99M. Demeule (2001) Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. International Journal of Cancer 93, 62-66

100M.W. Nabors (1991) Multidrug resistance gene (MDR1) expression in human brain tumors. Journal of Neurosurgery 75, 941-946

101M. Mohri , H. Nitta and J. Yamashita (2000) Expression of multidrug resistance-associated protein (MRP) in human gliomas. Journal of Neurooncology 49, 105-115

102Y. Zhang (2004) Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. Journal of Pharmacology and Experimental Therapeutics 311, 449-455

103C. Calatozzolo (2005) Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. Journal of Neurooncology 74, 113-121

104A.M. Bleau (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226-235

106S.P. Cole (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654

107A.T. Nies (2004) Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1–ABCC6), in human brain. Neuroscience 129, 349-360

108S.M. Dombrowski (2001) Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42, 1501-1506

110H. Potschka , M. Fedrowitz and W. Loscher (2003) Multidrug resistance protein MRP2 contributes to blood–brain barrier function and restricts antiepileptic drug activity. Journal of Pharmacology and Experimental Therapeutics 306, 124-131

111H. Potschka and W. Loscher (2001) Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport 12, 2387-2389

113W. Loscher and H. Potschka (2002) Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. Journal of Pharmacology and Experimental Therapeutics 301, 7-14

114H. Sun (2001) Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochemical and Biophysical Research Communications 284, 863-869

115M. Leggas (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Molecular and Cellular Biology 24, 7612-7621

116L.A. Doyle (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 95, 15665-15670

118R.W. Robey (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Reviews 26, 39-57

119H.C. Cooray (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13, 2059-2063

120S. Hori (2004) Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). Journal of Neurochemistry 90, 526-536

121S. Cisternino (2004) Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood–brain barrier. Cancer Research 64, 3296-3301

122T. Eisenblatter and H.J. Galla (2002) A new multidrug resistance protein at the blood–brain barrier. Biochemical and Biophysical Research Communications 293, 1273-1278

123Y.J. Lee (2005) Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood–brain barrier: a minor role of breast cancer resistance protein. Journal of Pharmacology and Experimental Therapeutics 312, 44-52

124R. Zhao (2009) Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood–brain barrier. Drug Metabolism and Disposition 37, 1251-1258

125J. Enokizono (2008) Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metabolism and Disposition 36, 995-1002

127S. Agarwal (2010) Role of breast cancer resistance protein (ABCG2/BCRP) in the distribution of Sorafenib to the brain. Journal of Pharmacology and Experimental Therapeutics 336, 223-233

128N.A. de Vries (2007) P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clinical Cancer Research 13, 6440-6449

130Y. Chen (2009) P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. Journal of Pharmacology and Experimental Therapeutics 330, 956-963

131J.S. Lagas (2009) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clinical Cancer Research 15, 2344-2351

132S. Agarwal (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. Journal of Pharmacology and Experimental Therapeutics 334, 147-155

133H. Kodaira (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. Journal of Pharmacology and Experimental Therapeutics 333, 788-796

134J.S. Lagas (2010) Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Molecular Cancer Therapeutics 9, 319-326

135Y. Tanaka (2005) Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochemical and Biophysical Research Communications 326, 181-187

136S. Hofer and K. Frei (2007) Gefitinib concentrations in human glioblastoma tissue. Journal of Neurooncology 82, 175-176

137R.K. Jain (2007) Angiogenesis in brain tumours. Nature Reviews. Neuroscience 8, 610-622

138R.J. Gilbertson and J.N. Rich (2007) Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nature Reviews. Cancer 7, 733-736

139D.L. Silbergeld and M.R. Chicoine (1997) Isolation and characterization of human malignant glioma cells from histologically normal brain. Journal of Neurosurgery 86, 525-531

140S. Spiegl-Kreinecker (2002) Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. Journal of Neurooncology 57, 27-36

141X. Decleves (2002) Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. International Journal of Cancer 98, 173-180

142M. Dean , T. Fojo and S. Bates (2005) Tumour stem cells and drug resistance. Nature Reviews. Cancer 5, 275-284

143H. Bronger (2005) ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Research 65, 11419-11428

144O. Bahr (2003) P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. Brain Pathology 13, 482-494

145C.T. Kuan (2010) MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer 10, 468

146H. Dai (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. Journal of Pharmacology and Experimental Therapeutics 304, 1085-1092

147S. Bihorel (2007) Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood–brain barrier. Journal of Neurochemistry 102, 1749-1757

148J.F. Leis (2004) Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leukemia and Lymphoma 45, 695-698

149J.W. Polli (2008) The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metabolism and Disposition 36, 695-701

150J.J. Yang (2010) P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metabolism Letters 4, 201-212

152E.C. de Lange and M. Danhof (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clinical Pharmacokinetics 41, 691-703

153S. Hofer , K. Frei and H.P. Rutz (2006) Gefitinib accumulation in glioblastoma tissue. Cancer Biology and Therapy 5, 483-484

154D. McKillop (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics 4, 641-649

156D.J. Stewart (1983) Concentration of vinblastine in human intracerebral tumor and other tissues. Journal of Neurooncology 1, 139-144

157D.J. Stewart (1984) Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. Journal of Neurooncology 2, 133-139

158J.O. Blakeley (2009) Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. Journal of Neurooncology 91, 51-58

159E. Bell Jr. and L.J. Karnosh (1949) Cerebral hemispherectomy; report of a case 10 years after operation. Journal of Neurosurgery 6, 285-293

160Y. Matsukado , C.S. Maccarty and J.W. Kernohan (1961) The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. Journal of Neurosurgery 18, 636-644

163P.R. Lockman (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clinical Cancer Research 16, 5664-5678

164L. Rosso (2009) A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Research 69, 120-127

165J.R. Molina (2010) Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 12, 453-463

166S.K. Singh (2004) Identification of human brain tumour initiating cells. Nature 432, 396-401

168S. Bao (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760

169A.M. Bleau , J.T. Huse and E.C. Holland (2009) The ABCG2 resistance network of glioblastoma. Cell Cycle 8, 2936-2944

170E. Nakai (2009) Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Investigation 27, 901-908

172A. Shervington and C. Lu (2008) Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Investigation 26, 535-542

173M. Westphal (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5, 79-88

174F.J. Attenello (2008) Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Annals of Surgical Oncology 15, 2887-2893

175H.C. Bock (2010) First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurgical Review 33, 441-449

176D.S. Bidros , J.K. Liu and M.A. Vogelbaum (2009) Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncology 6, 117-125

177S. Kunwar (2010) Phase III randomized trial of CED of IL13-PE38QQR vs gliadel wafers for recurrent glioblastoma. Neuro-oncology 12, 871-881

178Z. Lidar (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. Journal of Neurosurgery 100, 472-479

179R.A. Kroll and E.A. Neuwelt (1998) Outwitting the blood–brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42, 1083-1099; discussion 1099–1100

180T. Nomura , T. Inamura and K.L. Black (1994) Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Research 659, 62-66

181W.A. Hall (2006) Osmotic blood–brain barrier disruption chemotherapy for diffuse pontine gliomas. Journal of Neurooncology 77, 279-284

182J.A. Boockvar (2010) Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood–brain barrier disruption for recurrent malignant glioma. Journal of Neurosurgery 114, 624-632

183C. Lhomme (2008) Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. Journal of Clinical Oncology 26, 2674-2682

184R.W. Carlson (2006) A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Investigation 24, 677-681

185P. Ruff (2009) A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemotherapy and Pharmacology 64, 763-768

186L.D. Cripe (2010) Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 116, 4077-4085

187C.M. Kruijtzer (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. Journal of Clinical Oncology 20, 2943-2950

188A.S. Planting (2005) A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 55, 91-99

M.E. Berens and A. Giese (1999) “…those left behind.” Biology and oncology of invasive glioma cells. Neoplasia 1, 208-19

J.S. Lagas , M.L. Vlaming and A.H. Schinkel (2009) Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Molecular Interventions 9, 136-45

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *